Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 111, Issue 2, 2003, Pages 97-103

  Forst, Thomas ^a   Eriksson, J W ^b   Strotmann, H J ^c   Bai, S ^d   Brunelle, R ^d   Gulliya, K S ^d   Gack, S ^d   Gudat, U ^d  

^a Institute for Clinical Research and Development   (Germany)

^b Medicinkliniken   (Sweden)

^c Ctr for Diabet/Nutritional Med   (Germany)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

C peptide; Early diabetes type 2; Glibenclamide; HbA1c; Insulin lispro; Proinsulin

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; PROINSULIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGE OF ONSET; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0037397290     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39237     Document Type: Article

References (53)

1. Agardh CD, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982; 5: 322-325
2. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984; 33: 634-642
3. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188-195
4. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261: F571-F577
5. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-1239
6. Bastyr EJ, III, Johnson ME, Trautmann ME, Anderson JH, Jr., Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999; 21: 1703-1714
7. Bowsher RR,Wolny JD, Frank BH. A rapid and sensitive radioimmuno-assay for the measurement of proinsulin in human serum. Diabetes 1992; 41: 1084-1090
8. Bruce DG, Chisholm DJ, Storlien LH, Borkman M, Kraegen EW. Mealtime intranasal insulin delivery in type 2 diabetes. Diabet Med 1991; 8: 366-370
9. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-744
10. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105
11. Calles-Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 1987; 36: 1167-1172
12. Ceriello A: Acute hyperglycaemia and oxidative stress generation. Diabet Med 1997; 14 (Suppl 3): S45-S49
13. Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E. Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism 1996 a; 45: 498-501
14. Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-928
15. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996 b; 39: 469-473
16. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-931
17. DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia 1981; 21: 165-171
18. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001; 17: 164-174
19. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997, 20: 1539-1542
20. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-234
21. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002; 51 (Suppl 1): S117-S121
22. Hanefeld M, Fischer S, Julius S, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up. Diabetologia 1996; 39: 1577-1583
23. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144: 229-235
24. Hanley AJ, McKeown-Eyssen G, Harris SB, Hegele RA, Wolever TM, Kwan J, Connelly PW, Zinman B. Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition. Diabetes Care 2001; 24: 1240-1247
25. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M. Prandial glycaemia after a carbohydrate-rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-629
26. Hosker JP, Burnett MA, Matthews DR, Turner RC. Suppression of insulin secretion by falling plasma glucose levels is impaired in type 2 diabetes. Diabet Med 1988; 5: 856-860
27. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. Diabetes 1994; 43: 396-402
28. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of longterm glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356
29. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993; 10: 27-32
30. Kawamori R, Bando K, Yamasaki Y, Kubota M, Watarai T, Iwama N, Shichiri M, Kamada T. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects. Diabetes Care 1989; 12: 680-685
31. Kraegen EW, Young JD, George EP, Lazarus L. Oscillations in blood glucose and insulin after oral glucose. Horm Metab Res 1972; 4: 409-413
32. Lefebvre P, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med 1998; 15: S63-S68
33. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996; 39: 503-514
34. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515
35. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 1996; 17: 1337-1344
36. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390
37. Muhlhauser I, Sawicki PT, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia 1997; 40: 1492-1493
38. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PM, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects [see comments]. Diabetologia 1990; 33: 532-537
39. Owens DR,Jones MK, Hayes TM, Heding LG, Alberti KG, Home PD, Burrin JM. Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin. Lancet 1981; 2: 118-122
40. Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 1998; 47: 637-643
41. Paterson KR, Wilson M, Kesson CM, Buchan M, Roberts M, Reith SB, Davidson E. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy. Diabet Med 1991; 8: 40-43
42. Poitout V, Robertson RP. An integrated view of beta-cell dysfunction in type-11 diabetes. Annu Rev Med 1996; 47: 69-83
43. Polonsky KS. Non-insulin dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783
44. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
45. Robbins DC, Jaspan J, Vasquez B, Van Cauter E. Biphasic patterns of peripheral insulin and glucose levels after lunch in normal subjects. Diabetes Care 1987; 10: 293-299
46. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality [published erratum appears in Diabetologia 1999; 42: 1444]. Diabetologia 1999; 42: 1050-1054
47. Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, Hanefeld M. Increased intima-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care 1999; 22: 333-338
48. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999; 22: 920-924
49. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),-Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-720
50. Turner RC, McCarthy ST, Holman RR, Harris E. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976; 1: 1252-1254
51. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988; 31: 355-360
52. Yudkin JS. Circulating proinsulin-like molecules. J Diabetes Complications 1993; 7: 113-123
53. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey SG. Concentrations of proinsulin-like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002; 45: 327-336